These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28683709)

  • 1. [Linagliptin-induced liver toxicity].
    Bartolomé-García E; Sanz-Márquez S; Pérez-Encinas M
    Farm Hosp; 2017 Jul; 41(4):561-562. PubMed ID: 28683709
    [No Abstract]   [Full Text] [Related]  

  • 2. [Liver injury induced by linagliptine and sitagliptine: it' a class effect?].
    Patier de la Peña JL; González-García A; López-Castellanos G; Sobrino-Grande C
    Rev Clin Esp (Barc); 2014; 214(1):54-5. PubMed ID: 24287076
    [No Abstract]   [Full Text] [Related]  

  • 3. [Acute cholestatic hepatitis induced by glimepiride].
    Sitruk V; Mohib S; Grando-Lemaire V; Ziol M; Trinchet JC
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1233-4. PubMed ID: 11173739
    [No Abstract]   [Full Text] [Related]  

  • 4. Maculopapular drug eruption induced by linagliptin.
    Zheng M; Yoshimoto N; Muramatsu K; Ito T; Ujiie H; Shimizu H
    Australas J Dermatol; 2018 Nov; 59(4):e287-e288. PubMed ID: 29624647
    [No Abstract]   [Full Text] [Related]  

  • 5. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
    Kim ES; Deeks ED
    Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bullous pemphigoid associated with linagliptin treatment in diabetic patients with chronic kidney disease.
    Sánchez López-Muelas B; Muray Cases S; Illán Gómez F; García Guzmán G; Arjonilla Sampedro ME
    Endocrinol Diabetes Nutr (Engl Ed); 2019 May; 66(5):338-339. PubMed ID: 30630688
    [No Abstract]   [Full Text] [Related]  

  • 7. Glibenclamide and liver disease.
    Petrogiannopoulos C; Zacharof A
    Diabetes Care; 1997 Jul; 20(7):1215. PubMed ID: 9203475
    [No Abstract]   [Full Text] [Related]  

  • 8. Case report. Pseudohepatotoxicity of metformin.
    Swislocki AL; Noth R
    Diabetes Care; 1998 Apr; 21(4):677-8. PubMed ID: 9571371
    [No Abstract]   [Full Text] [Related]  

  • 9. [Meta-analysis shows: insulin sensitizer is safe for the liver].
    MMW Fortschr Med; 2002 Oct; 144(40):47. PubMed ID: 12440297
    [No Abstract]   [Full Text] [Related]  

  • 10. Linagliptin-induced bullous pemphigoid.
    Esposito I; Moretta G; Peris K; De Simone C
    Int J Dermatol; 2017 Dec; 56(12):1467-1469. PubMed ID: 28762465
    [No Abstract]   [Full Text] [Related]  

  • 11. Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al.
    Osei SY; Koro CE; Cobitz AR; Kolatkar NS; Stender M
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1244-6. PubMed ID: 19655316
    [No Abstract]   [Full Text] [Related]  

  • 12. Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et al.
    Beiderbeck AB; Sakaguchi M
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1247-9. PubMed ID: 19842093
    [No Abstract]   [Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
    Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glimepiride-induced acute hepatitis].
    Dusoleil A; Condat B; Sobesky R; Pelletier G; Buffet C
    Gastroenterol Clin Biol; 1999 Oct; 23(10):1096-7. PubMed ID: 10592884
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis and Characterization of Process-Related Impurities of Antidiabetic Drug Linagliptin.
    Huang Y; He X; Wu T; Zhang F
    Molecules; 2016 Aug; 21(8):. PubMed ID: 27517889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatotoxic reaction associated with metformin and chlorpropamide treatment].
    Crespo Valadés E; Ortega Gómez A; Alvarado Izquierdo MI; Magro Ledesma D
    Rev Clin Esp; 1999 Feb; 199(2):118-9. PubMed ID: 10216414
    [No Abstract]   [Full Text] [Related]  

  • 17. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
    Tan X; Hu J
    Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute hepatotoxicity caused by repaglinide.
    Nan DN; Hernández JL; Fernández-Ayala M; Carrascosa M
    Ann Intern Med; 2004 Nov; 141(10):823. PubMed ID: 15545689
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
    Rizos CV; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acarbose-induced acute severe hepatotoxicity.
    Carrascosa M; Pascual F; Aresti S
    Lancet; 1997 Mar; 349(9053):698-9. PubMed ID: 9078205
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.